Research Reports
Arch Pharmalabs Unlisted Shares
Arch Pharmalabs Share Price
PHYSICAL
PRIVATE LIMITED
Price Chart
1W
1M
1Y
MAX
High
₹110
Low
₹110
Return
-
Arch Pharmalabs Essentials
As of April 30, 2026, Arch Pharmalabs, Unlisted Shares are trading at ₹110.00 per share and face value is ₹10.00/share, with a 52-week high of ₹110.00 and 52-week low of ₹110.00. The minimun lot size is 1850 shares, and the shares are traded on NSDL and CDSL.
ISIN
INE182F01017
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Face Value
10
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total Shares
15,19,23,076
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Market Cap
1,671.15 Cr
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
Profit After Tax
124.95 Cr
It is the final profit left over after subtracting all operating and non operating items from net revenue.
Total Revenue
1,340.98 Cr
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
P/E
13.72
It is a valuation parameter that measures the company's current share price relative to its per-share earnings. Generally, high P/E is Overvalued & low P/E is Undervalued.
Sector
Health Care
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Sub-sector
Pharmaceuticals
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category
Delisted
Category is defined as a class or division of things regarded as having particular shared characteristics.
Cashflow - Operations
42.49 Cr
It indicates the amount of money a company brings in from its ongoing and regular operations over a fixed period of time.
About Arch Pharmalabs
- Arch Pharmalabs established on 2nd April 1993 is a pharmaceutical company aligned across two business verticals viz. Products and Services. Their Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. They have evolved their business and have, over the years, extended from manufacturing APIs and Intermediates to add CRAMS to their offerings, which has significant potential for the growth of our business.
- The company operates three state-of-the-art facilities for API manufacturing: the Vitalife Site in Gurgaon, the Oncology Site in Tarapur, and the Dombivli Site in New Mumbai. Additionally, it has four facilities dedicated to intermediate manufacturing: the Merven Site and Watsol Site in Hyderabad, and the Badlapur Site and Taloja Site in Mumbai.
- Arch Pharmalabs have a diversified portfolio product mix of more than 120 products (over 65 APIs and over 55 Intermediates) across various therapeutic segments including side chains of semi–Synthetic Isoxazole Penicillins under Antibiotics, Lipid Lowering Agents, Oncology, Anti-Platelet Agents, Anti-Asthmatic, Anti-Retroviral, Decongestant, Anti-Herpes, Anti-Malarial, NSAIDs, Anti-Anginal segments.
Want to See a Detailed Investment Analysis?
Explore in-depth financial analysis, performance metrics, and key disclosures.
Arch Pharmalabs Media
News
Articles
Videos
NCLT rejects JM Financial Asset Reconstruction's plea in Arch Pharmalabs case
22 May 2024
• The Economic Times
FinMin reviews bankruptcy proceedings of Arch Pharma Labs, Among other high-profile cases.
05 May 2024
• Money control
Mitsui & Co buys additional 25% stake in Arch Pharmalabs for Rs 372 crore
16 Sep 2012
• economictimes
Arch Pharmalabs
₹ 110
